Abstract

The invention is concerned with the use of a peptide comprising the N-terminal sequence

Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro--Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg

or any allelic variant or derivative of said peptide possessing the biological property of matching the inducible VE-cadherin binding motif on the Bβ-chain (i.e. $B\beta_{15-42}$) of human fibrin for the preparation of a pharmaceutical preparation for the treatment of shock, more specifically of hemorrhagic shock.